Harnessing the Potential of Dual Payload ADCs Across Disease Areas with AI-first Approach to ADCs
1:45 pm - Tuesday 9th March 2027
- AI-first, engineering-led approach to drug discovery and development underpins our dual-payload ADC technology
- Applying AI-guided payload selection to rationally combine complementary biological mechanisms for distinct therapeutic challenges
- Integrating computational linker optimisation, site-specific conjugation and stable linker chemistry with scalable, manufacturable design to optimise efficacy, minimise off-target toxicity and accelerate differentiated ADC candidates from design to the clinic
